

Effects of variations in access to care for children with atopic dermatitis



Elaine C. Siegfried, Amy S. Paller, Paola Mina-Osorio, Francis Vekeman, Mandeep Kaur

1. Department of Pediatrics, Division of Dermatology, Saint Louis University and Cardinal Glennon Children's Hospital, St. Louis, MO, USA

2. Health Economics and Outcomes Research, Medical Affairs, Regeneron

Abstract: (600 Limit)

An estimated 50% of children in the US are Medicaid-insured. Access to care for patients enrolled in Medicaid programs is an ongoing concern in the United States. Several studies have shown that patients enrolled in Medicaid are less likely to gain outpatient access to specialty providers. A number of factors, including unfavorable fee-for-service reimbursement, longer wait times for payments, and higher clinic non-attendance rates, contribute to the dearth of specialists accepting Medicaid patients. Skin disease is very common in children, prompting up to 30% of all primary care pediatric visits. Atopic dermatitis, a chronic inflammatory skin disease characterized by eczematous lesions and intense pruritus, is the most common inflammatory skin disease in children, with an estimated prevalence in the United States of about 11–13% among children less than 18 years of age. Up to one-third of these patients are estimated to have moderate-to-severe disease, along with a higher risk of atopic and non-atopic morbidities compared with children without AD. The burden of AD is substantial, especially in children with moderate-to-severe disease and their caregivers. Chronic sleep disturbance related to persistent

pruritus profoundly affects daily functioning, quality of life, and psychosocial health AD in children is also associated with poorer performance in school, difficulties forming social relationships and participating in sports, and increased rates of anxiety, depression, and even suicidal ideation.

Biography: (200 Limits)

Amy S. Paller, Elaine C. Siegfried and Paola Mina-Osorio contributed equally to the data analysis and interpretation, and drafting and critical revision of the article. Health Economics and Outcomes Research, Medical Affairs, Regeneron Pharmaceuticals,

About Research Topic: (200 Limit)

Results suggest barriers in accessing specialty care for all children with AD and significant differences in management between commercially and Medicaid-insured children. These disparities in treatment and access to specialty care may contribute to poor AD control, especially in Medicaid-insured patients.



About Institution: (200 Limit)

Northwestern University is a private research university in Evanston, Illinois. Founded in 1851, Northwestern is the oldest chartered university in Illinois and is ranked among the most prestigious academic institutions in the world. Chartered by the Illinois General Assembly in 1851, Northwestern was established to serve the former Northwest Territory. The university was initially affiliated with the Methodist Episcopal Church, but soon grew to be non-sectarian. In 1896, Northwestern

References: (15 to 20)

1. Zeng Y, Lin Y, Wang X, et al. Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus. Clin

[Rheumatic](#). 2020;39:2619–29.

2. 2016 ACR/ARHP annual meeting abstract supplement. Arthritis Rheumatic 2016; 68(S10): 1–4550.

3. Frizzler MJ, Salazar M. Diversity and origin of rheumatologic autoantibodies. *Clan Microbial* 1991;4(3):256–69.

4. Zing Y, Zhang Y, Lin Y, Wang X et al. The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythematosus with disease activity. *Clin Ext Med* 2021; 1–9

5 Kim HA, Jeon JY, Choi GS, et al. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. *Clin Immunol*. 2008;128(2):277–83.

6.de Lema GP, Maier H, Nieto E, et al. Chemokine expression precedes

inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. *J Am Soc Nephrol*. 2001;12(7):1369–82.

7.Kulkarni O, Anders HJ. Chemokines in lupus nephritis. *Front Biosci*. 2008;13:3312–20.

8. Howe HS, Leung BPL. Anti-cytokine autoantibodies in systemic lupus erythematosus. *Cells*. 2019;9(1):72.

9. Richmond A, Thomas HG. Purification of melanoma growth stimulatory activity. *J Cell Physiol*. 1986;129(3):375–84.

10. Bechara C, Chai H, Lin PH, Yao Q, Chen C. Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis and other inflammatory conditions. *Med Sci Monit*. 2007;13(6):RA87–90.